UK MHRA approves aumolertinib to treat non-small cell lung cancer
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Subscribe To Our Newsletter & Stay Updated